In the case of grades 3 and 4 gliomas, the presence of CDKN2A mutations represents an independent risk factor, in terms of low survival and poor prognosis, but the same was not highlighted in low-grade gliomas [45,46,47]. Here, CDKN2A is linked to central nervous system cancer.